EGFR and non-small cell lung carcinoma: Osimertinib, a third-generation EGFR TKI, is the current standard of care for the treatment of EGFR ex19del and L858R NSCLC, with demonstrated median progression-free survival (PFS) and overall survival (OS) of 18.9 months and 38.6 months, respectively9,10.